Samuel Chung

Samuel Chung, PhD, currently serves as a Senior Scientist in Cell Biology at ReCode Therapeutics, having previously held a similar position at Ambagon Therapeutics where responsibilities included co-leading a cross-functional team and developing chemical biology tools. Prior experience includes serving as Lead Scientist in Discovery Biology at BridgeBio, focusing on lung mucosal biology and Cystic Fibrosis strategy, as well as a Postdoctoral Researcher at the University of Kansas Medical Center, where significant funding was secured for research on e-cigarette vapor exposure and lung health. Samuel Chung began academic training with a PhD in Pharmacology & Toxicology from the University of California, Davis, following a BS in Biological Sciences from the University of California, Merced.